NCT06675383 SCREENING AFTER STROKE - ATRIAL FIBRILLATION
| NCT ID | NCT06675383 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Vestre Viken Hospital Trust |
| Condition | Atrial Fibrillation (AF) |
| Study Type | OBSERVATIONAL |
| Enrollment | 410 participants |
| Start Date | 2024-11-01 |
| Primary Completion | 2027-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 410 participants in total. It began in 2024-11-01 with a primary completion date of 2027-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
As much as 20-30% of all strokes are attributed to atrial fibrillation (AF), making the detection of AF highly important, as AF-related strokes are largely preventable with optimal treatment. Therefore, most guidelines recommend screening patients for AF after a stroke, although the optimal timing and choice of monitoring device for screening remain undefined. Our aim is to investigate whether AF screening as early as possible after stroke symptom onset provides a higher detection rate compared to screening after discharge. Additionally, we aim to determine if a 3-lead ECG device provides a higher detection rate compared to a 1-lead patch recorder.
Eligibility Criteria
Inclusion Criteria: * 18 years or older * Ischemic stroke * Without known AF or those with previously diagnosed paroxysmal AF exhibiting sinus rhythm upon admission Exclusion Criteria: * AF at hosptial admission * Unable or unwilling to provide informed consent * A life expectancy of less than one year
Contact & Investigator
Håkon Ihle-Hansen, MD PhD
STUDY DIRECTOR
Vestre Viken HF
Frequently Asked Questions
Who can join the NCT06675383 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Atrial Fibrillation (AF). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06675383 currently recruiting?
Yes, NCT06675383 is actively recruiting participants. Contact the research team at haaihl@vestreviken.no for enrollment information.
Where is the NCT06675383 trial being conducted?
This trial is being conducted at Sogneprest Munthe-kaas Vei 100, Norway.
Who is sponsoring the NCT06675383 clinical trial?
NCT06675383 is sponsored by Vestre Viken Hospital Trust. The principal investigator is Håkon Ihle-Hansen, MD PhD at Vestre Viken HF. The trial plans to enroll 410 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.